Prospect: information for the patient
CABOMETYX 20mg film-coated tablets
CABOMETYX 40mg film-coated tablets
CABOMETYX 60mg film-coated tablets
cabozantinib
Read this prospect carefully before starting to take this medication, as it contains important information for you.
What is CABOMETYX
CABOMETYX is a cancer medication that contains the active ingredient cabozantinib. It is used in adults to treat:
CABOMETYX is also used to treat locally advanced or metastatic differentiated thyroid cancer, a type of cancer in the thyroid gland, in adults when treatments with radioactive iodine and anticancer medications can no longer stop the progression of the disease.
CABOMETYX can be administered in combination with nivolumab for advanced kidney cancer. It is essential that you also read the prospectus for nivolumab. If you have any questions about these medications, consult your doctor.
How does CABOMETYX work?
CABOMETYX blocks the action of proteins called tyrosine kinase receptors (RTK), which are involved in cell growth and the development of new blood vessels that supply blood to these cells. These proteins may be present in high quantities in cancer cells, and by blocking their action, this medication can slow the rate at which the tumor grows and help interrupt the blood supply that cancer needs.
Do not take CABOMETYX
Warnings and precautions
Consult your doctor or pharmacist before starting to take CABOMETYX:
Consult your doctor if you experience any of the above.
You may need treatment, or your doctor may decide to change the dose of CABOMETYX or stop treatment completely. See also section 4 “Possible side effects”.
You should also inform your dentist that you are taking this medicine. It is important for you to have good oral care during treatment.
Children and adolescents
CABOMETYX is not recommended for use in children and adolescents. The effects of this medicine in people under 18 years old are unknown.
Other medicines and CABOMETYX
Inform your doctor or pharmacist if you are taking, or have recently taken, any other medicine, including those bought without a prescription. This is because CABOMETYX may affect how other medicines work. Also, some medicines may affect how CABOMETYX works. This may require your doctor to change the dose you take. You should inform your doctor about any medicine, but particularly if you are taking:
CABOMETYX with food
Avoid taking products containing grapefruit juice while taking this medicine, as they may increase the levels of this medicine in the blood.
Pregnancy, breastfeeding, and fertility
It is essential to avoid pregnancy during treatment with CABOMETYX.If you or your partner can become pregnant, you should use suitable contraceptive methods during treatment and for at least four months after stopping treatment. Discuss suitable contraceptive methods with your doctor while taking this medicine (see also “Other medicines and CABOMETYX”).
Consult your doctor if you or your partner become pregnant, or if you or your partner plan to become pregnant, during treatment with this medicine.
Talk to your doctor BEFORE starting to take this medicineif you or your partner are planning or have already planned to have a child once treatment has finished. There is a possibility that treatment with this medicine may affect your fertility.
Women taking this medicine should stop breastfeeding during treatment and for at least four months after treatment has finished, as cabozantinib and/or its metabolites may be excreted in breast milk and be harmful to the infant.
If you take this medicine while using oral contraceptives, oral contraceptives may be ineffective. You should also use a barrier method of contraception (e.g., condom or diaphragm) while taking this medicine and for a minimum period of 4 months after treatment has finished.
Driving and operating machines
Be cautious when driving or operating machines. Be aware that treatment with CABOMETYX may make you feel tired or weak and may affect your ability to drive and operate machines.
CABOMETYX contains lactose
This medicine contains lactose (a type of sugar).If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medicine.
CABOMETYX contains sodium
This medicine contains less than 1 mmol (23 mg of sodium) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Continue taking this medication until your doctor decides to stop treatment. If you experience severe side effects, your doctor may decide to change the dose or stop treatment earlier than planned. Your doctor will tell you if you need to adjust your dose.
You should take CABOMETYX once a day. The usual dose is 60 mg, however your doctor will decide what dose is appropriate for you.
When this medication is administered in combination with nivolumab for the treatment of advanced kidney cancer, the recommended dose of CABOMETYX is 40 mg per day.
Do not take CABOMETYX with food.
Do not eat any food for at least two hours before and during one hour after taking this medication.
Swallow the tablet with a full glass of water. Do not crush the tablets.
If you take more CABOMETYX than you should
If you have taken more of this medication than you were told to, speak with a doctor or go to the hospital immediately with the tablets and this leaflet.
If you forget to take CABOMETYX
If you interrupt treatment with CABOMETYX
Interrupting treatment may interrupt the effect of your medication. Do not stop treatment with this medication unless you have spoken with your doctor.
When this medication is administered in combination with nivolumab, nivolumab will be administered first followed by CABOMETYX.
See the nivolumab leaflet to understand how this medication is used. If you have any other questions about the use of this medication, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. If you experience side effects, your doctor may tell you to take CABOMETYX at a lower dose. Your doctor may also prescribe other medicines to help control the side effects.
Inform your doctor immediately if you notice any of the following side effects, as you may need urgent medical treatment:
Other side effects that can occur with CABOMETYX alone:
Frequent side effects(can affect up to 1 in 10 people)
Frequent side effects(can affect up to 1 in 10 people)
Rare side effects(can affect up to 1 in 100 people)
Unknown frequency (proportion of affected people unknown)
The following side effects have been reportedwith CABOMETYX in combination with nivolumab:
Frequent side effects(can affect more than 1 in 10 people)
Frequent side effects(can affect up to 1 in 10 people)
Rare side effects(can affect 1 in 100 people)
Unknown frequency (proportion of affected people unknown)
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and the label of the bottle and box after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. In this way, you will help protect the environment.
CABOMETYX Composition
The active ingredient is (S)-malate of cabozantinib.
CABOMETYX 20mg film-coated tablets: each tablet contains (S)-malate of cabozantinib, equivalent to 20mg of cabozantinib.
CABOMETYX 40mg film-coated tablets: each tablet contains (S)-malate of cabozantinib, equivalent to 40mg of cabozantinib.
CABOMETYX 60mg film-coated tablets: each tablet contains (S)-malate of cabozantinib, equivalent to 60mg of cabozantinib.
The other components are:
Appearance of CABOMETYX and packaging
The CABOMETYX 20mg film-coated tablets are yellow, round, and have no score, with the inscription «XL» on one side and «20» on the other.
The CABOMETYX 40mg film-coated tablets are yellow, triangular, and have no score, with the inscription «XL» on one side and «40» on the other.
The CABOMETYX 60mg film-coated tablets are yellow, oval, and have no score, with the inscription «XL» on one side and «60» on the other.
CABOMETYX is available in packaging containing a plastic bottle with 30film-coated tablets.
The bottle contains three desiccant gel containers and a polyester plug to prevent damage to the film-coated tablets.Keep these desiccant containers and the polyester plug in the bottle and do not swallow them.
Marketing Authorization Holder
Ipsen Pharma
65 quai Georges Gorse
92100 Boulogne-Billancourt
France
Responsible Person
Patheon France
40 Boulevard de Champaret
38300 Bourgoin Jallieu, France
Tjoapack Netherlands B.V.
Nieuwe Donk 9
4879 AC Etten-Leur
Netherlands
Rottendorf Pharma GmbH
Ostenfelderstrasse 51 – 61
D-59320 Ennigerloh
Germany
For more information about this medicine, please contact the local representative of the marketing authorization holder.
België/Belgique/Belgien, Luxembourg/Luxemburg Ipsen NV België /Belgique/Belgien Tel: + 32 9 243 96 00 | Italia Ipsen SpA Tel: + 39 02 39 22 41 |
Latvija Ipsen Pharma representative office Tel: +371 67622233 | |
Ceská republika Ipsen Pharma, s.r.o. Tel: + 420 242 481 821 | Lietuva Ipsen Pharma SAS Lietuvos filialas Tel. + 370 700 33305 |
Danmark, Norge, Suomi/Finland, Sverige, Ísland Sverige/Ruotsi/Svíþjóð Tlf/Puh/Tel/Sími: +46 8 451 60 00 | Magyarország IPSEN Pharma Hungary Kft. Tel.: +36 1 555 5930 |
Deutschland, Österreich Ipsen Pharma GmbH Deutschland Tel.: +49 89 2620 432 89 | Nederland Ipsen Farmaceutica B.V. Tel: + 31 (0) 23 554 1600 |
Eesti Centralpharma Communications OÜ Tel: +372 60 15 540 | Polska Ipsen Poland Sp. z o.o. Tel.: + 48 22 653 68 00 |
Ελλ?δα, Κ?προς, Malta Ipsen Μονοπρ?σωπη EΠΕ Ελλ?δα Τηλ: + 30 -210 984 3324 | Portugal Ipsen Portugal - Produtos Farmacêuticos S.A. Tel: + 351 21 412 3550 |
España Ipsen Pharma, S.A.U. Tel: + 34 936 858 100 | România Ipsen Pharma România SRL Tel: + 0 (021) 231 27 20 |
France Ipsen Pharma Tel: + 33 1 58 33 50 00 | Slovenija PharmaSwiss d.o.o. Tel: + 386 1 236 47 00 |
Hrvatska Bausch Health Poland sp. z.o.o. podružnica Zagreb Tel: +385 1 6700 750 | Slovenská republika Ipsen Pharma, organizacná zložka Tel:+ 420 242 481 821 |
Ireland, United Kingdom (Northern Ireland) Ipsen Pharmaceuticals Limited. Tel: +44 (0)1753 62 77 77 |
Last update of this leaflet: October 2023
Other sources of information
For detailed information about this medicine, please visit the website of the European Medicines Agency:http://www.ema.europa.eu.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.